Home › Bladder Cancer › New York › The Bronx
Bladder Cancer clinical trials in The Bronx, NY
4 studies for Bladder Cancer are looking for participants at sites in and around The Bronx (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
RecruitingPhase 1
- Montefiore Medical Center, The Bronx
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
RecruitingPhase 2
- Montefiore Medical Center, The Bronx
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
RecruitingPhase 2
- Montefiore Medical Center, The Bronx
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RecruitingPhase 1
- North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists, The Bronx
About Bladder Cancer
Bladder cancer symptoms range from lower back pain to blood in your urine. Read about important risk factors and find a list of treatments available
More about Bladder Cancer on MedlinePlus
Bladder Cancer trials in other cities
- New York City, NY36 studies
- Nashville, TN31 studies
- Houston, TX31 studies
- Dallas, TX27 studies
- Boston, MA26 studies
- Washington, DC26 studies
- Los Angeles, CA25 studies
- Baltimore, MD24 studies
- Philadelphia, PA23 studies
- Edison, NJ23 studies
- St. Louis, MO22 studies
- Chicago, IL21 studies
Other studies in The Bronx
- Non-Small Cell Lung Cancer23 studies
- Breast Cancer18 studies
- Acute Myeloid Leukemia15 studies
- Prostate Cancer12 studies
- Lung Cancer12 studies
- Cardiovascular Disease11 studies
- Cancer (all types)10 studies
- Asthma10 studies
- Heart Failure10 studies
- Head and Neck Squamous Cell Carcinoma9 studies
- Myelodysplastic Syndromes9 studies
- Colorectal Cancer9 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.